?????? ????????????? ??????????????????? ???????????????????????????????????????????????????????????Negotiations in excess of the 2022 reauthorization recommend that sector priorities include improved application of true-environment proof, regulatory certainty, and enhanced interaction between FDA and business through the drug application course of